RxDoctor Payments Data

Carrie Hess, DPM

Podiatrist · Tucson, AZNPI 1396915377

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 75 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by Smith+Nephew at 41.6% of the total. 2025 is the largest year on record at $770, more than ten times the $68 reported in 2019.

$1,894in general payments, 2019–2025

Across 75 payments — averaging $25.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$787
  • Orthofix Medical, Inc.$189
  • Medshape, Inc.$150
  • Globus Medical$85
  • Solventum Corporation$62
  • Bioventus LLC$53
  • plus $568 from 22 others

What the payments were for

  • Food & beverage$1,894100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,894 in reported general payments places this provider in the 70th percentile of 151 podiatrist providers in Arizona.

See all podiatrist providers in Arizona

Medicare billing

Part B allowed, 2024
$530,878
Medicare patients
469
Services billed
3,447

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Doxycycline Hyclate68$663
Ketoconazole18$421
Betamethasone Dipropionate11$378
Gabapentin33$354
Terbinafine Hcl17$320
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip11$213

Paid to pharmacies, not to this prescriber.

Other podiatrist in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →